Gilead Sciences ( GILD ) announced encouraging top line results from a phase III study (GS US 337 0113 n=341) …read more
Gilead’s HCV Combination Therapy Data Looks Promising – Analyst Blog
- by Bob Mitchell
Gilead Sciences ( GILD ) announced encouraging top line results from a phase III study (GS US 337 0113 n=341) …read more